Table 1.
Baseline characteristics of TOURMALINE study patients included in the efficacy population
| Parameter | Value, N=112 |
|---|---|
| Age | |
| Years, mean (SD) | 67 (12) |
| ≥65 yr, n (%) | 73 (65) |
| Men, n (%) | 73 (65) |
| Race, n (%) | |
| White | 92 (82) |
| Black | 14 (13) |
| Other | 4 (4) |
| Ethnicity, n (%) | |
| Hispanic/Latino | 63 (56) |
| Non-Hispanic/Latino | 49 (44) |
| Serum potassium, mEq/L, mean (SD) | 5.39 (0.40)a |
| <5.5, n (%) | 66 (59) |
| ≥5.5, n (%) | 46 (41) |
| eGFR, mean (SD), ml/min per 1.73 m2 | 41 (26) |
| CKD, n (%) | 85 (76) |
| eGFR≥45 ml/min per 1.73 m2 | 16 (14) |
| eGFR<45 ml/min per 1.73 m2 | 69 (62) |
| Diabetes mellitus, n (%) | 92 (82) |
| Heart failure, n (%) | 10 (9) |
| Hypertension, n (%) | 105 (94) |
| RAAS inhibitors, n (%) | 66 (59) |
| β-Blocking agents, n (%) | 58 (52) |
| Non-RAAS diuretic, n (%) | 40 (36)b |
RAAS, renin-angiotensin-aldosterone system.
a
Baseline serum potassium is defined as the mean of serum potassium from the central laboratory on two consecutive days (day −1 and day 1) immediately before the first dose of patiromer.
b
All non-RAAS diuretics were potassium wasting.